18F-FDG对于乳腺癌模型小鼠治疗作用的研究

[目的] 探讨18氟-氟代脱氧葡萄糖（ 18F-FDG）诱导乳腺癌细胞的凋亡作用及分子机制。[方法] 使用0～7.4×10 6  Bq/mL 18F-FDG作用于体外培养乳腺癌细胞MCF-7,应用γ高能计数仪测定细胞摄取射线量;接种MCF-7细胞至24只雌性裸鼠腋下构建小鼠乳腺癌模型,成瘤后分别由尾静脉注射生理盐水、3.7 MBq、11.1 MBq和37 MBq 18F-FDG,观察肿瘤生长情况,Micro-animal PET进行瘤体显像;Western Blot方法检测肿瘤瘤体凋亡相关蛋白BCL-2及cleaved CASPASE-3表达情况。[结果] 体外MCF-7细胞摄取实验表明,在一定剂量范围内,随着射线剂量的增加,对数生长期的MCF-7细胞摄取射线剂量基本呈线性增长;治疗后,各治疗组小鼠肿瘤体积增长速度明显放缓,而高剂量组（11.1 MBq与37 MBq）较低剂量组（3.7 MBq）显示出更低的增长速度。Micro-animal PET显示荷瘤裸鼠的肿瘤部位可见 18F-FDG浓聚,治疗组浓聚程度低于对照组,且随着治疗剂量增加,浓聚程度亦随之降低。Western Blot结果显示注射 18F-FDG后,荷瘤裸鼠瘤体cleaved CASPASE-3相对表达量各治疗组（37 MBq、11.1 MBq、3.7 MBq 18F-FDG）分别为4.935±1.521、5.560±1.459及2.138±0.844,均高于对照组的0.019±0.049（P<0.05或P<0.01）,尽管在11.1 MBq剂量组与37 MBq剂量组间表达差异无显著性意义（P>0.05）,但两组均高于3.7 MBq剂量组（P<0.05）;BCL-2蛋白相对表达量分别为1.489±0.691、1.929±0.949、3.421±1.554,均低于对照组的5.143±1.813（P<0.05或P<0.01）,尽管11.1 MBq剂量组与37 MBq剂量组间差异无显著性意义（P>0.05）,但两组均低于3.7 MBq剂量组（P<0.05）。[结论] 18F-FDG在适量情况下,能下调肿瘤BCL-2蛋白的表达和激活CASPASE-3表达诱导乳腺癌细胞凋亡。     

18F-FDG和18F-FLT的PET-CT显像在肺结节鉴别诊断中的作用

观察比较18F-FDG和18F-FLT用于PET/CT在肺结节诊断的临床意义和价值,提高肺癌早期诊断的准确性和灵敏度,为临床准确、科学治疗肺内结节提供循证医学依据。     

横纹肌肉瘤的18F-FDG PET/CT表现

目的 探讨横纹肌肉瘤(RMS)的¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG) PET/CT表现，提高对RMS的认识及诊断准确率。方法 回顾性分析2012年10月至2022年2月郑州大学第一附属医院41例经病理证实的RMS患者的临床资料及¹⁸F-FDG PET/CT表现，比较不同病理分型RMS、成人与儿童RMS的肿瘤最大标准化摄取值(SUV_max)及肿瘤/肝脏最大标准化摄取值比值(TLR)。结果 41例患者中，胚胎型21例，腺泡型10例，梭形细胞型3例，多形型1例，类型不明6例。胚胎型RMS和其他病理类型RMS SUV_max分别为9.34±4.64与10.93±5.12,TLR分别为4.18±1.98与4.38±1.94,差异均无统计学意义(P>0.05)。儿童RMS和成人RMS SUV_max分别为9.22±4.35与10.41±5.43,TLR分别为4.46±1.67与3.96±2.37,差异均无统计学意义(P>0.05)。胚胎型及其他病理类型患者...     

18F-FDG与18F-PSMA-1007 PET/CT在前列腺癌诊断中的应用效果观察

[目的]探讨¹⁸F-FDG PET/CT与¹⁸F-PSMA-1007 PET/CT在诊断前列腺癌原发灶和转移灶中的应用价值.[方法]收集40例疑似前列腺癌患者的临床资料进行回顾性分析,所有患者均行¹⁸F-FDG PET/CT和¹⁸F-PSMA-1007 PET/CT检查,最终诊断以组织病理学检查结果为标准.分析比较两种显像剂在前列腺癌诊断中的灵敏度、特异度、准确度、阳性预测值、阴性预测值及曲线下面积(AUC);比较前列腺癌原发病灶、淋巴结转移灶及骨转移灶的最大标准摄取值(SUVmax)和病灶检出率;对血清tPSA水平、Gleason评分与原发灶的SUVmax值进行Spearman相关性分析.[结果]前列腺癌组tPSA水平及两种显像剂的SUVmax值均显著高于良性病变组(P<0.05).¹⁸F-PSMA-1007 PET/CT诊断前列腺癌的准确度和阳性预测值均显著高于¹⁸F-FDG PET/CT(P<0.05);¹⁸F-FD...     

18F-FDG PET/CT显像棕色脂肪摄取分析及护理

目的探讨在18F-FDG PET/CT检查中患者出现棕色脂肪组织(BAT)摄取的原因以及护理对应措施。方法回顾我院2010年4月～2012年4月行18F-FDG PET/CT检查出现棕色脂肪组织摄取的25例患者资料,总结分析棕色脂肪摄取的原因,并提出相应的护理对策。结果 BAT显影以对称性分布在颈部、锁骨上、腋下和胸椎旁为主。以中青年女性多见,大多集中冬季寒冷季节。在采取保暖等措施后,棕色脂肪显影明显减少。结论在冬季,对行18F-FDG PET/CT检查的青年女性,应注重御寒护理。     

18F-FDG PET/CT与CT检测鼻咽癌颈部转移淋巴结的对比研究

目的比较18F-FDG PET/CT与CT显像对鼻咽癌颈部转移淋巴结的诊断价值,为放射治疗靶区的勾画提供参考。方法40例病理确诊为鼻咽癌的患者,放疗前均行PET/CT及CT检查,并用双盲法将PET/CT与同期的CT诊断结果进行比较。结果CT检出咽旁间隙淋巴结2个,最大直径15.0 mm;PET/CT检出咽后及咽旁间隙淋巴结淋巴结各8个,最大直径4.0~15.0 mm,淋巴结摄取FDG均增高,SUV最大值2.9~14.1;CT检出双侧颈部淋巴结48个,最大直径8.0~25.0 mm,PET/CT检出70个(包括CT检出的48个淋巴结),最大直径4.0~25.0 mm;除1个淋巴结外,淋巴结摄取FDG均增高,SUV最大值3.4~11.2。结论18F-FDG PET/CT显像对鼻咽癌颈部转移淋巴结的诊断优于CT,对放疗靶区的勾画有较大的指导作用。     

乳腺癌EGFR表达与18F-FDG PET/CT代谢参数间的相关性

目的 分析乳腺癌表皮生长因子受体(EGFR)表达与¹⁸F-FDG PET/CT代谢参数间的相关性,并评价¹⁸F-FDG PET/CT代谢参数对乳腺癌EGFR阳性表达的预测效能。方法 回顾性分析2015年4月至2021年8月就诊于天津医科大学肿瘤医院的72例患者的临床资料,所有患者均于术前行¹⁸F-FDG PET/CT检查并经病理证实为乳腺癌,测量原发灶最大标准化摄取值(SUV_max)、肿瘤代谢体积(MTV)、糖酵解总量(TLG),分析EGFR表达状态与¹⁸F-FDG PET/CT代谢参数的相关性,通过受试者工作特征曲线(ROC)及Logistic回归分析评价原发灶¹⁸F-FDG PET/CT显像代谢参数对EGFR阳性表达的预测效能。结果 72例患者中EGFR阳性表达者29例,阴性表达者43例,EGFR阳性表达率为40.28%;EGFR阳性表达者SUVmax、TLG中位数分别为11.97、227.48,明显高于阴性者的7.00、27.72,差异均有统计学意义...     

18F-FDG PET在肺癌诊断中的应用

肺癌是危害人类健康的常见恶性肿瘤之一,孤立肺结节的影像检查应对其性质、转移、分期、分型及预后作出判断.常规的影像学手段,包括CT、MRI诊断肺癌效果均不能令人满意.     

骨髓坏死18F-FDG PET/CT与MRI对照分析

目的 探索骨髓坏死氟-18-脱氧葡萄糖(¹⁸F-fluorodeoxyglucose,¹⁸F-FDG)正电子发射断层显像/计算机断层显像(positron emission tomography/computed tomography, PET/CT)表现,提高对该病的认识。方法 回顾性分析9例磁共振成像(magnetic resonance imaging, MRI)诊断为骨髓坏死患者的PET/CT及临床资料,对照MRI影像,总结病变分布,选择最大病变,分析¹⁸F-FDG代谢特点及CT征象。结果 患者男6例,女3例,中位年龄28.0岁,均患淋巴瘤。MRI检查髋部6例、胸腰椎2例、膝部1例。6例髂骨病变,内部均为T1加权像(T1-weighted image, T1WI)高信号,T2脂肪抑制像(T2-fat suppressed image, T2FSI)低信号,伴T1WI边缘环状低信号,其中5例内部代谢减低,边缘代谢增高伴骨质硬化;1例密度及代谢未见异常,MRI显示病变狭长。2例脊柱病变T1WI呈等、低信号,T2FSI...     

正电子显像剂18F-FDG的制备与质量控制

目的研究正电子断层显像剂2-18F-2-脱氧-D-葡萄糖(18F-FDG)的制备与质量控制。方法采用回旋加速器,通过18O(p,n)18F核反应和亲核取代反应制备18F-FDG。对制备的18F-FDG进行质量控制研究。结果放射化学产率约为54％,用TLC法和HPLC法测定化学纯度均大于99％,放化纯度均大于95％,18F-FDG各项质量控制指标符合药典要求。结论制备的18F-FDG适用于临床PET。     

18F-FDG PET显像在肺癌纵隔淋巴结转移诊断中的应用

目的探讨~(18)F-FDG PET显像对肺癌肺门及纵隔淋巴结转移的诊断价值。方法41例手术病理证实为肺癌的患者,回顾分析其术前胸部PET对肺门、纵隔淋巴结转移的检出结果,与同期胸部CT检查对比,并以病理为标准。结果经理检出有肺门或纵隔淋巴结转移者18例,PET正确诊断17例,CT正确诊断10例;病理未见肺门或纵隔淋巴结转移者23例,PET正确诊断22例,CT正确诊断20例;~(18)F-FDG PET显像对肺门及纵隔淋巴结转移灶检出的灵敏度和准确性(分别为94.4%、95.1%)明显高于CT(分别为55.6%、73.2%)(P<0.05)。结论~(18)F-FDG PET显像对于肺癌纵隔及肺门淋巴结转移灶的检出具有明显优势,特别是对CT难以检出的小淋巴结转移灶有重要的临床价值,可为临床准确分期、确定治疗方案提供重要依据。     

18F-FDG positron emission tomography for mediastinal staging of lung cancer]

OBJECTIVE: To evaluate the diagnostic value of (18)F-FDG positron emission tomography (PET) in mediastinal staging of lung cancer. METHOD: A retrospective analysis of mediastinal staging was carried out in 41 cases of lung cancer by comparing the preoperative mediastinal FDG PET and CT findings with the pathological results. RESULTS: According to the pathological results, 18 patients had mediastinal metastasis, 17 of whom were correctly identified by FDG PET, and 10 by CT. Of the other 23 patients without mediastinal metastasis pathologically, 22 were correctly diagnosed by FDG PET and 20 by CT. The sensitivity and accuracy for diagnosis of regional mediastinal lymph node metastasis with FDG PET were 94.4% and 95.1%, obviously higher than those of CT (55.6% and 73.2%, P<0.05). CONCLUSION: FDG PET is a better alternative for mediastinal staging of lung cancer, specially for identification of small lymph node metastasis escaping detection by CT, to provide important evidence for clinical staging and treatment planning of lung cancer.     

18F-FDG-PET/CT在弥漫大B细胞淋巴瘤中的分期诊断价值

目的旨在对比18F-FDG-PET/CT与CT在弥漫大B细胞淋巴瘤（DLBCL）中的分期诊断价值,分析DLBCL病灶的18F-FDG-PET/CT显像及分布特点。方法32例以淋巴结病理确诊的DLBCL患者,同时以18F-FDG-PET/CT及CT评价分期,18F-FDG-PET/CT及CT测量肿瘤病灶的部位、大小及SUVmax,计算与纵隔大血管主动脉弓血池SUVmax比值（T/MB）。结果18F-FDG-PET/CT及CT检测DLBCL病灶的一致率为70.6%,其敏感性分别为100%、75.8%,特异性分别为96%、4%,阳性预测值分别为99.7%、91.5%,阴性预测值分别为100%、1.2%,假阳性率分别为4%、96%,假阴性率分别为0、24.2%,准确率为99.7%、70.9%。结论18F-FDG-PET/CT对DLBCL检测的敏感性、特异性均明显好于CT,对多种结外病灶尤其是骨骼侵润的诊断较CT具有优越性,能够协助临床准确分期。DLBCL病灶的18F-FDG-PET/CT显像分布特点及T/MB值可供临床医生参考。     

The possible value of ^18F-FDG positron emission tomography/ computerized tomography imaging in detection of atherosclerotic plaque

Objective To evaluate the clinical value with positron emission tomography/computerized tomography(PET/CT) imaging for the detection of vulnerable plaque in atherosclerotic lesions. MethodsSixty people with a age of over 60[mean age (69.2±7.1)years]underwent three dimension(3D) whole-body fluorine-18-2-fluoro-2-deoxy-D-glucose(JaF-FDG) PET/CT imaging and were evaluated retrospectively, including 6 cases assessed as normal and 54 cases with active atherosclerotic plaque. Fifty-four cases with SUVs and CT values in the aortic wall of high-FDG-uptake were measured retrospectively. These high-FDG-uptake cases in the aortic wall were divided into three groups according their CT value. Cases in group I had high uptake in atherosclerotic lesions of the aortic wall with CT value of less than 60 Hu(soft plaque). Cases in group 2 had high uptake with CT value between 60-100 Hu (intermediate plaque). Cases in group 3 had high uptake with CT value more than 100 Hu(calcified plaque). Group 4 was normal. Results In group 1, there were 42 high-FDG-uptake sites (average SUV 1.553±0.486). In group 2, there were 30 high-FDG-uptake sites(average SUV 1.393 ± 0.296). In group 3, there were 36 high-FDG-uptake sites(average SUV 1.354 _ 0.189). In group 4, there were 33 normal-FDG-uptake sites (average SUV was 1.102± 0.141). The SUVs showed significant difference among the four groups(F= 678.909, P= 0.000). There were also significant difference found between the normal-FDG-uptake group and the high-FDG-uptake groups(P = 0.000, 0.000, 0.001, respectively). ConclusionDifferent degrees of 18F-FDG uptake in active large atherosclerotic plaque were shown in different stages of atherosclerotic plaque formation. The soft plaque had the highest FDG uptake in this study. This suggested that 18F-FDG PET/CT imaging may be of great potential value in early diagnosis and monitoring of vulnerable soft plaque in atherosclerotic lesions.     

18F-FDG脑PET显像和VEEG在癫痫病灶定位中的价值比较

目的探讨18F-FDG脑PET显像和视频脑电图（VEEG）在癫痫灶定位中的价值及其联系。方法42例患者均行18F—FDG脑PET显像、VEEG,与术中脑电图（EcoG）比较。结果发作间期42例患者PET检查38例阳性,阳性率92．9％;42例患者VEEG阳性37例,阳性率89％;PET与VEEG检查完全一致或部分一致率分别为54．8％和19％;42例患者PET检查34例与术中EcoG相符,符合率80．9％;VEEG符合率60％。结论18F-FDG脑PET显像是定位诊断顽固性癫痫致痫灶的一种无创、灵敏、较VEEG更加准确的方法。     

18F-FDG positron emission tomography/computed tomography and the "underground map" appearance in imaging Horton's arteritis

A majority of the clinical use of positron emission tomography (PET)-computed tomography (CT) is related to cancer management. Its application in evaluating inflammatory diseases and pyrexia of unknown origin is becoming popular. We reviewed the fluorine-18-fluorodeoxyglucose PET-CT findings of an 80-year-old woman with nonspecific clinical presentation consisting of generalised malaise, moderately high fever and weight loss. Prior CT and magnetic resonance imaging were not helpful in providing a clinical diagnosis. The diagnosis was Horton's arteritis, and the patient responded well to high-dose steroids.     

~(18)F-FDG PET-CT在肝脏肿瘤消融治疗中的作用

目的 探讨用~(18)F脱氧葡萄糖(FDG)PET-CT指导肝恶性肿瘤消融治疗的可行性.方法 对13例肝脏恶性肿瘤消融治疗后仍有肿瘤残留病灶的患者,在PET-CT检查结果指导下,再次进行射频消融术及无水乙醇瘤内注射治疗.结果 13例患者首次消融后残留的病灶共35个,参照PET-CT结果二次消融治疗后31个病灶呈放射性缺损,4个病灶仍有部分区域呈放射性浓聚,再次消融治疗后病灶完全呈放射性缺损.结论 ~(18)F-FDG PET-CT能灵敏、直观、准确地显示消融术后肿瘤组织坏死和残留情况;对消融后残留肿瘤的再次消融治疗有很好的指导作用.

Abstract：

Objective To assess the value of ~(18)F-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography ~(18)F-FDG PET-CT) in ultrasound-guided local ablation of malignant liver tumors. Methods Thirteen patients with 35 local residual tumor foci following previous tumor ablation underwent ~(18)F-FDG PET-CT and ultrasound-guided local ablation with intratumoral alcohol injection. Results After the second local ablation guided by ~(18)F-FDG PET-CT and ultrasound, radioactive defects were detected in the corresponding location in 31 of the 35 residual foci, and after the third local ablation, the other 4 foci also showed radioactive defects. Conclusions ~(18)F-FDG PET-CT can sensitively and accurately identify tissue necrosis and residual tumors, and serves as an excellent approach for ultrasound-guided local ablation of local residual tumors.     

Multiple and incidentally found cancers detected by 18F-FDG positron emission tomography/CT at one examination

During the initial 8 months period of 18F-FDG PET/CT examination in our institution eleven cases of double cancers were detected. Eight cases were simultaneous second cancers and 3 cases are consecutive cancers. All cases are clinical ones and were referred from both outside hospitals and our own hospital. 18F-FDG PET/CT examination were utilized either to determine the extent of tumor or to stage the cancer or to detect recurrent tumors during the follow-up period. During the 8-months period 964 cases were studied. Therefore, the detection rates of simultaneous and consecutive cancers are 0.83% and 0.31% respectively. All together the detection rate of double cancer was 1.14%. To gain the general conception of double cancers the authors reviewed the autopsy registry of Japanese Society of Pathology during the four years from 2000 through 2003, and tabulated the combination of primary and second cancers. Frequently found combination of cancers were cancers of the thyroid, lung, stomach, liver, biliary tract, colon, rectum, and prostate. 18F-FDG PET/CT examination seems to be very useful in the management of cancer patients in terms of whole patient care.     

Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms

Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) has been widely used not only for detecting and staging malignant tumours but also for monitoring therapy response and for differentiating malignant lesions from benign lesions. However, the sensitivity of 18F-FDG PET for hepatocellular carcinoma (HCC) is low. Recent research about the novel drug shows that the sensitivity of 11C-acetate PET for HCC is higher than that of 18F-FDG PET and 11C-acetate also indicates tumour cell differentiation. 18F-FDG PET proved to be highly sensitive in detecting hepatic metastases from different primaries. 18F-FDG PET has also been shown to be useful and more accurate than conventional imaging modalities in demonstrating the effect of local treatments in liver tumours. With the development of small animal imaging, animal research about 18F-FDG PET is increasing.